Controlled amplification in oncology dose-finding trials

Area of Science:

• Oncology
• Clinical Trial Design
• Pharmacometrics

Background:

• Traditional oncology trials focus on identifying the maximum tolerated dose (MTD) for cytotoxic agents.
• Modern early-phase trials for non-cytotoxic agents incorporate multiple objectives, including determining the recommended Phase 2 dose (RP2D).
• Conventional methods like the Continual Reassessment Method (CRM) collect limited data on doses below the MTD.

Purpose of the Study:

• To investigate the concept of "controlled amplification" in dose-finding designs.
• To precisely define and analyze methods that amplify data collection at lower dose levels.
• To evaluate a specific design that utilizes controlled amplification for improved RP2D determination.

Main Methods:

• Review and definition of "controlled amplification" strategies.
• Inclusion of dose expansion cohorts and patient backfilling as amplification methods.
• Analysis of a novel dose-finding design incorporating controlled amplification.

Main Results:

• Controlled amplification, through dose expansion and backfilling, enhances data collection on doses near and below the MTD.
• This strategy addresses the possibility that lower doses may be more effective ("less is more").
• The study presents observations and evaluates a specific design exploiting controlled amplification.

Conclusions:

• Controlled amplification is a valuable strategy for modern oncology dose-finding trials.
• These methods improve the efficiency and information yield for RP2D determination.
• Further investigation into specific designs utilizing controlled amplification is warranted.